Endologix to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015

IRVINE, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2014 financial results, which will take place on Wednesday, February 25, 2015 after the close of the market.

Endologix will hold a conference call on Wednesday, February 25, 2015 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.endologix.com.

After the live webcast, a replay of the webcast and a transcript of the call will remain available online from the investor relations page of Endologix’s website, www.endologix.com, through March 25, 2015. In addition, a telephonic replay of the call will be available until March 11, 2014. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13599879.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

CONTACT: COMPANY CONTACT:

   Endologix, Inc.
   John McDermott, CEO
   Shelley Thunen, CFO
   (949) 595-7200
   www.endologix.com

INVESTOR CONTACTS:

   The Ruth Group
   Nick Laudico (646) 536-7030
   Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media